12 results about "Diabetes Therapy" patented technology

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said individual, and / or at least three matched pre-prandial glucose measurement values and postprandial glucose measurement values at the same meal from said individual. Further contemplated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instructions, when executed by the processing unit, causes the processing unit to perform the computer-implemented method of the present invention.

Techniques for data analysis and user guidance are provided for determining and providing one or more therapies to a user based on where the user is or will be in their menstrual cycle. In certain embodiments, a method of personalizing diabetes therapy based on information related to a user's menstrual cycle is provided. The method includes measuring blood glucose measurements of the user using a glucose monitoring system. The method also includes receiving information related to the user's menstrual cycle. The method further includes determining a therapy for the user to achieve a target blood glucose during a sub-phase or phase of the user's menstrual cycle based on at least one of historical data associated with the user and historical data associated with a stratified group.

The application discloses a multi-modal diabetes dynamic treatment effect evaluation method, relates to the technical field of data processing, and unifies a time axis and marks reliability for multi-source data through an adaptive interpolation and alignment strategy; peak values and abnormal fluctuations within one to two weeks are detected and recognized based on a short-term window, a short-term change amount and a risk prompt are generated; a multi-layer attention or a Transformer is used to fuse data on a monthly scale, comprehensive long-term treatment effect indexes and key inflection points are extracted; short-term quantitative results and long-term indexes are brought into a multi-target reward mechanism through a continuous learning and interactive real-time feedback module, model parameters are iterated online, and clinical intervention suggestions are output; external events are quantitatively marked, and identification and response to sudden situations are strengthened through a bias injection mode. High-quality integration of multi-source heterogeneous data, short-term and long-term multi-level analysis are realized, and the precision and timeliness of diabetes dynamic monitoring and intervention are significantly improved.

The application discloses an intelligent self-adaptive ablation system, an ablation catheter and a method for type 2 diabetes treatment, and belongs to the technical field of medical devices. The system comprises an intelligent control host and an electrode unit library. The intelligent control host integrates a main control processor, a motion prediction decision unit, an intelligent driving control module and an intelligent energy control module. The electrode unit library comprises a plurality of electrode units with different structures. The main control processor and the motion prediction decision unit automatically select an optimal electrode unit based on the duodenal cavity tract anatomical form obtained by a sensing component. The intelligent driving control module receives instructions to drive the selected electrode unit to adapt to the cavity environment. The intelligent energy control module provides controlled ablation energy to the electrode unit. Through the "sensing-decision-execution" closed loop, the application realizes self-adaptive and precise ablation treatment in the duodenal dynamic environment, thereby solving the problems of passive control strategy and lack of prospective compensation in the prior art which depend on a single electrode form.

The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention relates to the technical field of biological medicine and gene therapy, in particular to a nucleic acid delivery system for targeting pancreatic beta cells and application of the nucleic acid delivery system. The composition comprises a nano-composite formed by a cationic polymer modified by a targeting ligand and siRNA (small interfering Ribonucleic Acid), the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is the siRNA of the target DYRK1A (DYRK1A). The invention provides a brand-new pancreatic beta cell targeted delivery platform for gene therapy of type 2 diabetes mellitus. The platform realizes beta cell function regeneration by accurately regulating and controlling DYRK1A gene expression, has targeting property, safety and high efficiency, and provides a new strategy with wide clinical application prospect for diabetes treatment.

The invention discloses an intelligent self-adaptive ablation system, ablation catheter and method for treating type 2 diabetes mellitus, and belongs to the technical field of medical instruments. The system comprises an intelligent control host and an electrode unit library, wherein the intelligent control host integrates a main control processor, a motion prediction decision unit, an intelligent driving control module and an intelligent energy control module; the electrode unit library comprises a plurality of electrode units with different structures. The main control processor and the motion prediction decision-making unit automatically select the optimal electrode unit based on the duodenal cavity anatomical form obtained by the sensing assembly; the intelligent driving control module receives an instruction to drive the selected electrode unit to adapt to the cavity environment; the intelligent energy control module provides controlled ablation energy to the electrode unit. The self-adaptive and accurate ablation treatment in a duodenum dynamic environment is realized through a'sensing-decision-execution 'closed loop, so that the problems of dependence on a single electrode form, passive control strategy and lack of prospective compensation in the prior art are solved.

The invention provides an efficient screening method of immobilized alpha-amylase and a corn stigma source alpha-amylase inhibitor based on a magnetic carrier, and mainly solves the technical problems that the existing diabetes drugs have obvious side effects and the screening efficiency of natural active ingredients is low. In order to solve the problem of drug tolerance generally existing in treatment of type 2 diabetes mellitus, a magnetic MOF carrier is used in the scheme, and efficient immobilization of alpha-amylase is realized through a synergistic strategy of amino functional surface modification and glutaraldehyde crosslinking. The immobilized enzyme system and ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF / MS) form a combined platform, and a three-stage analysis process of magnetic enzyme reaction-precise molecular weight screening-MS / MS structure confirmation is established. Compared with the traditional tedious screening period, the technology can complete the discovery and confirmation of the active components in a short time, and provides an efficient and industrialized solution for the discovery of the plant-derived hypoglycemic lead compound.

Techniques are provided for data analysis and user guidance for determining and providing one or more treatments to a user based on a location of the user in or to be in its menstrual cycle. In certain embodiments, a method of personalizing diabetes treatment based on information related to a user's menstrual cycle is provided. The method includes measuring a blood glucose measurement of a user using a glucose monitoring system. The method also includes receiving information related to a menstrual cycle of the user. The method further includes determining a treatment of the user based on at least one of historical data associated with the user and historical data associated with the hierarchical group to achieve a target blood glucose during a sub-stage or stage of a menstrual cycle of the user.